
    
      This was a Phase 2, multicenter, multinational, prospective, randomized, double-blind,
      placebo-controlled, parallel study designed to assess the efficacy and safety of sapropterin
      dihydrochloride in subjects with intermittent claudication (IC) caused by peripheral arterial
      disease (PAD). Subjects who met initial screening criteria were monitored criteria and that
      dosages of permitted concomitant medications were stable.
    
  